Committee Decisions
Committee List
- ASPH DTC
- Commissioning Intentions
- East Surrey CCG Medicines Programme Board
- East Surrey ICP MOG
- Epsom St Helier NDAIG
- ESCCG sub-committee of North Place Alliance Clinical Strategy Committee (formerly Clinical Executive
- Guildford and Waverley MOG
- Medicines Optimisation Operational Group (MOOG)
- Not Set
- NW Surrey CCG Medicines Optimisation Group
- Primary Care Medicines Optimisation Clinical reference Group (PCMOCRG)
- RSCH DTC
- Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
- Surrey Downs CCG MOG
- Surrey Downs CCG Prescribing Leads Meeting
- Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
- Surrey Heartlands Medicines Optimisation Board (MOB)
- Surrey Heartlands Medicines Safety Committee (MSC)
- Surrey Medicines Commissioners Group
- Surrey Priorities Committee
Decisions : Surrey Medicines Commissioners Group
Records returned : 54.
Community Pharmacy Surrey & Sussex (CPSS) have produced a briefing to explain the changes to the pharmacy home delivery services - see briefing paper below
Additional information relating to community pharmacy services across Surrey and Sussex can be found on the CPSS website
https://communitypharmacyss.co.uk/
The Surrey Medicines Commissioners Group approved the non-meedical prescrier framework for use across Surrey.
Hepatitis B for the AT RISK group - Public Health England have provided advice about the management and prioritisation of Hepatitis B vaccines during periods of short supply and a plan for the phased re-introduction of hepatitis B vaccine for the lower priority groups.
NOTE - Hepatitis B has a BLACK traffic light status for use in travel - see "Travelling abroad" link on the right of the screen for further information
Combined Hepatitis A/B for the AT RISK group - Public Health England have provided advice about the management and prioritisation of Hepatitis vaccines during periods of short supply and a plan for the phased re-introduction of hepatitis vaccine for the lower priority groups.
NOTE - Hepatitis A/B has a BLACK traffic light status for use in travel - see "Travelling abroad" link on the right of the screen for further information
From 1st April 2019 both pregabalin and gabapentin will be classified as a schedule 3 Controlled Drug. As such, the arrangements through which patients obtain these medicines will change.
The Surrey Medicines Commissioners Group have developed a patient template letter for local adaption - see below.
In addition, NHSE have produced a patient hand-out that is also available below
From 1st April 2019 both pregabalin and gabapentin will be classified as a schedule 3 Controlled Drug. As such, the arrangements through which patients obtain these medicines will change.
The Surrey Medicines Commissioners Group have developed a patient template letter for local adaption - see below.
In addition, NHSE have produced a patient hand-out that is also available below
From 1st April 2019 both pregabalin and gabapentin will be classified as a schedule 3 Controlled Drug. As such, the arrangements through which patients obtain these medicines will change.
The Surrey Medicines Commissioners Group have developed a patient template letter for local adaption - see below.
In addition, NHSE have produced a patient hand-out that is also available below
From 1st April 2019 both pregabalin and gabapentin will be classified as a schedule 3 Controlled Drug. As such, the arrangements through which patients obtain these medicines will change.
The Surrey Medicines Commissioners Group have developed a patient template letter for local adaption - see below.
In addition, NHSE have produced a patient hand-out that is also available below
The Surrey Medicines Commissioners Group agreed that the Surrey Heartlands Managing Diabetes in Care Homes resource was appropriate for local adoption.
See CCG specific documents below
Quetiapine IR should be prescribed generically. The Seroquel brand was assigned a BLACK traffic light status by the PCN in May 2017
SABP have updated (Jan 2018) a number of resources aimed at supporting the use of IR quetiapine in preference to the XL formulations - see below
A shared-care Information Sheet for prescribers can also be found below.
Where quetiapine is used in Behavioural and Psychological Symptoms of Dementia (BPSD), please see PAD page for this indication (search BPSD or see link below)
It is recommended that tramadol modified release preparations are prescribed by BRAND - see UKMI Branded Prescribing Recommendations document below. The locally preferred brand for modified-release, TWICE DAILY dosing is Marol® Marol® is available across all of the twice-daily dose ranges, already represents the most commonly prescribed tramadol brand locally and nationally and remains one of the most cost-effective tramadol MR choices. Patients currently receiving generically written prescriptions should be reviewed with a view to change the prescribing to a cost-effective brand.
It is recommended that buprenorphine patches are prescribed by BRAND - see UKMI Branded Prescribing Recommendations document below. The locally preferred brand for buprenorphine 7-day patches is Butec® Butec® is available across all of the dose ranges, already represents the most commonly prescribed brand nationally (>50%), and is considerably less costly than the originator brand BuTrans. Patients currently receiving generically written prescriptions should be reviewed with a view to change the prescribing to a cost-effective brand.
A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their salbutamol PSDs.
This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it.
Please contact your local Medicines Management Team for assistance
Patient Specific Directions (PSDs) are often used to enable non-medical practitioners (practice nurses, health care assistants) to administer specific medicines for specific conditions. A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Denosumab PSDs. This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it. Please contact your local Medicines Management Team for assistance
A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their testosterone injection (Nebido) PSDs.
This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it.
Please contact your local Medicines Management Team for assistance
A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Zoladex PSDs.
This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it.
Please contact your local Medicines Management Team for assistance
A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Prostap PSDs.
This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it.
Please contact your local Medicines Management Team for assistance
A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Vitamin B12 PSDs.
This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it.
Please contact your local Medicines Management Team for assistance
In the small cohort of patients who require BOTH the hepatitis A and B for travel purposes, the vaccines should be supplied separately with the hepatitis A on FP10 prescription and the hepatitis B as a private supply.
Hepatitis B vaccination for TRAVEL purposes is not commissioned under the NHS and should be prescribed / supplied privately for this indication
evidence-based, application-in-practice oriented resources to support quality prescribing in the NHS - see "overview for clinicians" document below.
Where agreed as appropriate and supportive of local initiatives, PrescQIPP resources will be made available on the PAD and will be used / implemented by local Medicines Management Teams. CCG NHS logos will be added to locally endorsed PrescQIPP documents.
For non-PrescQIPP subscribers there are numerous resources available on the PrescQIPP website that have been released for use by all.
For more information about PrescQIPP and to access a variety of resources, visit the PrescQIPP website https://www.prescqipp.info/
See guide below
UKMI have produced a Q&A document to highlight these reports and have recommended that NDAIDs are avoided in children suffering from this infection.
Paracetamol is the recommended alternative for symptomatic management.
Please see Q&A document for full information
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below.
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below.
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
The cards are available for practices to order through usual NHS stationery supply routes.
See an example of the Anticoagulant Alert Card in the document below
UKMI Q&A for branded prescribing recommendations states that fentanyl patches are available as matrix and reservoir formulations; Patient familiarity with one brand is important. Generic prescribing is therefore not recommended and is considerably more costly. Matrifen (matrix) was agreed as a cost effective brand for primary care prescribing and is currently the most commonly prescribed brand of fentanyl patch amongst the Surrey CCGs. Mezolar matrix patches and Mylafent patches are similarly lower cost. Note: patches must not be cut because damage to the rate-limiting membrane can lead to a rapid release of fentanyl resulting in overdose. If the prescriber intends the patch to be cut (NB: unlicensed and not recommended by the MHRA) then the prescription must specify a brand of matrix formulation patch.
It is recommended that slow-release and longer-acting diltiazem products are prescribed by brand.
Following consideration of product price and current prescribing levels, the following were agreed as cost-effective preferred diltiazem brands for primary care:
- Twice daily – Angitil SR capsules (available in all three strengths)
- OR Tildiem Retard for patients preferring a tablet (although not available as 180mg strength)
- Once daily – Zemtard XL
It is recommended that slow-release and longer-acting diltiazem products are prescribed by brand.
Following consideration of product price and current prescribing levels, the following were agreed as cost-effective preferred diltiazem brands for primary care:
- Twice daily – Angitil SR capsules (available in all three strengths)
- OR Tildiem Retard for patients preferring a tablet (although not available as 180mg strength)
- Once daily – Zemtard XL
Following consideration of product price and current prescribing levels, the following were agreed as cost-effective preferred nifedipine brands for primary care:
o Twice daily – Coracten SR for patients preferring a capsule OR Adipine MR for patients preferring a tablet
o Once daily – Coracten XL for patients preferring a capsule OR Adipine XL for patients preferring a tablet
Following consideration of product price and current prescribing levels, the following were agreed as cost-effective preferred nifedipine brands for primary care:
o Twice daily – Coracten SR for patients preferring a capsule OR Adipine MR for patients preferring a tablet
o Once daily – Coracten XL for patients preferring a capsule OR Adipine XL for patients preferring a tablet
This discussion follows a number of requests received by GPs to prescribe
Prescribe generically.
Note - the branded product Ursofalk 250mg capsules were considered BLACK at the May 2017 PCN